H
Husseini K. Manji
Researcher at Janssen Pharmaceutica
Publications - 65
Citations - 4963
Husseini K. Manji is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Treatment-resistant depression & Bipolar disorder. The author has an hindex of 29, co-authored 65 publications receiving 3662 citations. Previous affiliations of Husseini K. Manji include Johnson & Johnson & Johnson & Johnson Pharmaceutical Research and Development.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial
Ella Daly,Jaskaran Singh,Maggie Fedgchin,Kimberly Cooper,Pilar Lim,Richard C. Shelton,Michael E. Thase,Andrew Winokur,Luc Van Nueten,Husseini K. Manji,Wayne C. Drevets +10 more
TL;DR: In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose related and response appeared to persist for more than 2 months with a lower dosing frequency.
Journal ArticleDOI
Impaired mitochondrial function in psychiatric disorders.
Husseini K. Manji,Tadafumi Kato,Nicholas A. Di Prospero,Seth Ness,M. Flint Beal,Michael Krams,Guang Chen +6 more
TL;DR: There is a growing body of evidence to suggest that impaired mitochondrial function may affect key cellular processes, thereby altering synaptic functioning and contributing to the atrophic changes that underlie the deteriorating long-term course of these illnesses.
Journal ArticleDOI
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova,Ella Daly,Madhukar H. Trivedi,Kimberly L. Cooper,Rosanne Lane,Pilar Lim,Christine Mazzucco,David Hough,Michael E. Thase,Richard C. Shelton,Patricio Molero,Eduard Vieta,Malek Bajbouj,Husseini K. Manji,Wayne C. Drevets,Jaskaran Singh +15 more
TL;DR: Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy and is supported by the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.
Journal ArticleDOI
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis
TL;DR: The evidence reviewed here suggests that lithium's neurotrophic effects in BD are an example of an old molecule acting as a new proof-of-concept agent, which will likely lead to the development of not only improved therapeutics for BD, but to neurotrophic enhancers that could prove useful in the treatment of many other illnesses.
Journal ArticleDOI
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Jaskaran Singh,Maggie Fedgchin,Ella Daly,Liwen Xi,Caroline Melman,Geert De Bruecker,André Tadić,Pascal Sienaert,Frank Wiegand,Husseini K. Manji,Wayne C. Drevets,Luc Van Nueten +11 more
TL;DR: A rapid onset of robust antidepressant effects was observed in patients with TRD after a 40-minute IV infusion of either .20mg/kg or .40 mg/kg of esketamine, suggesting the lower dose may allow for better tolerability while maintaining efficacy.